Edition:
United States

People: Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

176.30USD
26 Jul 2017
Change (% chg)

$2.45 (+1.41%)
Prev Close
$173.85
Open
$173.37
Day's High
$176.46
Day's Low
$172.12
Volume
769,779
Avg. Vol
977,800
52-wk High
$189.48
52-wk Low
$119.37

Eastham, Karin 

Ms. Karin Eastham, CPA, is Independent Director of Illumina, Inc. since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc. a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc. a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc. a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc. a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc. a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc. a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD 400,076
Long-Term Incentive Plans, USD --
All Other, USD 90,000
Fiscal Year Total, USD 490,076

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jay Flatley

2,991,900

Francis deSouza

8,408,830

Sam Samad

--

Marc Stapley

2,856,620

Garret Hampton

--

Omead Ostadan

2,840,100
As Of  31 Dec 2016